These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 7812092)
21. Contribution of virus and immune factors to herpes simplex virus type I-induced corneal pathology. Hendricks RL; Tumpey TM Invest Ophthalmol Vis Sci; 1990 Oct; 31(10):1929-39. PubMed ID: 2170289 [TBL] [Abstract][Full Text] [Related]
22. Immunopathology of herpetic stromal keratitis: discordance in CD4+ T cell function between euthymic host and reconstituted SCID recipients. Thomas J; Rouse BT J Immunol; 1998 Apr; 160(8):3965-70. PubMed ID: 9558104 [TBL] [Abstract][Full Text] [Related]
23. Resistance to herpetic stromal keratitis in immunized B-cell-deficient mice. Daheshia M; Deshpande S; Chun S; Kuklin NA; Rouse BT Virology; 1999 Apr; 257(1):168-76. PubMed ID: 10208930 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Milligan GN; Dudley-McClain KL; Chu CF; Young CG Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519 [TBL] [Abstract][Full Text] [Related]
25. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640 [TBL] [Abstract][Full Text] [Related]
26. Involvement of CD8+ T-cells in exacerbation of corneal scarring in mice. Osorio Y; Cai S; Hofman FM; Brown DJ; Ghiasi H Curr Eye Res; 2004; 29(2-3):145-51. PubMed ID: 15512961 [TBL] [Abstract][Full Text] [Related]
28. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes. Chentoufi AA; Dasgupta G; Christensen ND; Hu J; Choudhury ZS; Azeem A; Jester JV; Nesburn AB; Wechsler SL; BenMohamed L J Immunol; 2010 Mar; 184(5):2561-71. PubMed ID: 20124097 [TBL] [Abstract][Full Text] [Related]
29. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma. Gómez CE; Abaitua F; Rodríguez D; Esteban M Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077 [TBL] [Abstract][Full Text] [Related]
30. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D. Wyckoff JH; Osmand AP; Eisenberg RJ; Cohen GH; Rouse BT Immunobiology; 1988 May; 177(2):134-48. PubMed ID: 2456985 [TBL] [Abstract][Full Text] [Related]
31. T cell receptor V beta gene expression in experimental herpes stromal keratitis. Pedroza-Seres M; Goei S; Merayo-Lloves J; Dutt JE; Lee SJ; Arrunategui-Correa V; Foster CS Eye (Lond); 1995; 9 ( Pt 5)():599-604. PubMed ID: 8543080 [TBL] [Abstract][Full Text] [Related]
32. Native HSV glycoprotein D subunit vaccine: analysis of in vitro T-cell activation and antigen presentation. Ishizaka ST; Mishkin EM Viral Immunol; 1991; 4(3):187-93. PubMed ID: 1667262 [TBL] [Abstract][Full Text] [Related]
33. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Aurelian L; Smith CC; Wachsman M; Paoletti E Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130 [TBL] [Abstract][Full Text] [Related]
34. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization. Martin S; Mercadal CM; Weir JP; Rouse BT Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515 [TBL] [Abstract][Full Text] [Related]
35. Effect of herpes simplex virus-1 gD or gD-IL-2 DNA vaccine on herpetic keratitis. Inoue T; Inoue Y; Hayashi K; Shimomura Y; Fujisawa Y; Aono A; Tano Y Cornea; 2002 Oct; 21(7 Suppl):S79-85. PubMed ID: 12484704 [TBL] [Abstract][Full Text] [Related]
36. Synthetic glycoprotein D-related peptides protect mice against herpes simplex virus challenge. Eisenberg RJ; Cerini CP; Heilman CJ; Joseph AD; Dietzschold B; Golub E; Long D; Ponce de Leon M; Cohen GH J Virol; 1985 Dec; 56(3):1014-7. PubMed ID: 2999419 [TBL] [Abstract][Full Text] [Related]
37. [Herpes simplex virus retinitis. Role of the immune system in the animal experiment]. Zierhut M; Tamesis R; Hemady R; Foster CS Fortschr Ophthalmol; 1991; 88(6):740-7. PubMed ID: 1665474 [TBL] [Abstract][Full Text] [Related]
38. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge. Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710 [TBL] [Abstract][Full Text] [Related]
39. Epitope mapping of the 273-284 region of HSV glycoprotein D by synthetic branched polypeptide carrier conjugates. Hudecz F; Hilbert A; Mezö G; Mucsi I; Kajtár J; Bösze S; Kurucz I; Rajnavölgyi E Pept Res; 1993; 6(5):263-71. PubMed ID: 7504960 [TBL] [Abstract][Full Text] [Related]
40. Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide. Drew MD; Estrada-Correa A; Underdown BJ; McDermott MR J Gen Virol; 1992 Sep; 73 ( Pt 9)():2357-66. PubMed ID: 1383408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]